8 results about "Pityriasis" patented technology

This application provides the use of an antimicrobial peptide in the preparation of skin care products. The antimicrobial peptide of this application can effectively inhibit *Propionibacterium acnes* and *Malassezia*, thereby preventing skin problems such as acne, skin inflammation, and dandruff caused by the overgrowth of these two bacteria. Therefore, the antimicrobial peptide of this application has skin care uses in inhibiting acne, relieving skin inflammation such as folliculitis, pityriasis versicolor, and seborrheic dermatitis, and in inhibiting dandruff, and has significant practical value.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of XBD-173 or its pharmaceutically acceptable salts in the preparation of remedies for treating and / or preventing depigmentation diseases caused by pigment synthesis disorders, particularly in the preparation of remedies for treating and / or preventing vitiligo, leukoderma, pityriasis alba, and albinism. Experiments have shown that XBD-173 can significantly increase melanin synthesis and promote repigmentation in the dorsal lesions of vitiligo mice, while exhibiting no significant toxicity. In summary, XBD-173 has a clear mechanism of action, significant effects, and no significant side effects, demonstrating significant advantages and advancements compared to existing drugs.

The invention relates to application of Ro5-4864 or pharmaceutically acceptable salt in preparation of a medicine for treating and / or preventing melanocyte degeneration diseases caused by inflammatory immune response induced by oxidative stress. The melanocyte degeneration diseases caused by inflammatory immune response induced by oxidative stress comprise vitiligo, leukoplakia and pityriasis albicans. The Ro5-4864 and the pharmaceutically acceptable salt of the Ro5-4864, disclosed by the invention, inhibit continuous loss of melanocytes from oxidative stress, are strong in targeting effect and relatively small in side effect, and have remarkable advantages and progress compared with existing medicines.

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and / or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, tinea versicolor, pityriasis versicolor, tinea circinata, tinea pedis, tinea unguium, tinea manus, tinea cruris, tinea corporis, tinea faciei, tinea capitis, and / or tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

The present invention relates to a composition comprising at least one oxazoline, such as OX100, for inhibiting the growth of Malassezia yeasts and / or for preventing and / or treating conditions caused by Malassezia yeasts, seborrheic dermatitis, cradle cap, Malassezia folliculitis, dandruff, Pityriasis versicolor or Pityriasis capitis. The present invention also relates to a composition comprising at least one oxazoline such as OX100, at least one compound such as malic acid diester and a vegetable oil oleodistillate and / or arabinogalactan, and to the use of same for preventing and / or treating, in particular, affections caused by Malassezia yeasts, seborrheic dermatitis, cradle cap, Malassezia folliculitis, dandruff, Pityriasis versicolor or Pityriasis capitis.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.